Evidence map›Paper›PMID 38182161›Full record

ArticleLife science alliance2024

Intisar Koch, Maya Slovik, Yuling Zhang, Bingyu Liu, Martin Rennie, Emily Konz, Benjamin Cogne, Muhannad Daana, Laura Davids, Illja J Diets and 19 more

Open access · goldAbstract read
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 18 institutions in 7 countries.

Intisar KochPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.ORCID https://orcid.org/0009-0002-2640-660X
Maya SlovikFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.ORCID https://orcid.org/0009-0006-2933-4487
Yuling ZhangDepartment of Immunology, School of Biomedical Sciences, Shandong University, Jinan, PR China.
Bingyu LiuDepartment of Immunology, School of Biomedical Sciences, Shandong University, Jinan, PR China.
Martin RennieSchool of Molecular Biosciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0002-0799-3450
Emily KonzPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.ORCID https://orcid.org/0009-0003-5229-2148
Benjamin CogneNantes Université, CHU de Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France.
Muhannad DaanaChild Development Centers, Clalit Health Care Services, Jerusalem, Israel.
Laura DavidsDepartment of Neurosciences, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Illja J DietsDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Nina B GoldMassachusetts General Hospital for Children, Boston, MA, USA.
Alexander M HoltzDivision of Genetics & Genomics, Department of Pediatrics, Boston Children's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-1620-6519
Bertrand IsidorNantes Université, CHU de Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France.
Hagar Mor-ShakedFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Juanita Neira FresnedaDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Karen Y NiederhofferDepartment of Medical Genetics, University of Alberta, Edmonton, Canada.
Mathilde NizonNantes Université, CHU de Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France.
Rolph PfundtDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Meh SimonDepartment of Genetics, University Medical Center Utrecht, Utrecht, Netherlands.
Apa StegmannDepartment of Clinical Genetics, Maastricht University Medical Center, Maastricht, Netherlands.ORCID https://orcid.org/0000-0002-9736-7137
Maria J Guillen SacotoGeneDx, Gaithersburg, MD, USA.
Marijke WeversDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-8008-6008
Tahsin Stefan BarakatDepartment of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0003-1231-1562
Shira Yanovsky-DaganDepartment of Genetics, Hadassah Medical Center, Jerusalem, Israel.
Boyko S AtanassovDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID https://orcid.org/0000-0002-4878-9253
Rachel TothMRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.ORCID https://orcid.org/0000-0002-1337-0612
Chengjiang GaoDepartment of Immunology, School of Biomedical Sciences, Shandong University, Jinan, PR China.
Francisco BustosPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA Francisco.bustos@sanfordhealth.org.ORCID https://orcid.org/0000-0001-5457-4956
Tamar HarelFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel tamarhe@hadassah.org.il.ORCID https://orcid.org/0000-0003-3595-7075
Centre National de la Recherche Scientifique · FRHebrew University of Jerusalem · ILRadboud University Nijmegen · NLShandong University · CNBoston Children's Hospital · USUniversity of Sioux Falls · USChildren's Healthcare of Atlanta · USClalit Health Services · ILEmory University · USErasmus MC · NLGlasgow Life · GBHadassah Medical Center · ILMaastricht University · NLRoswell Park Comprehensive Cancer Center · USUniversity Medical Center Utrecht · NLUniversity of Alberta · CAUniversity of Dundee · GBUniversity of South Dakota · US

Funding

Pilot Project ProgramP30GM145398 · NIGMS · SANFORD RESEARCH/USD · PI W KEITH MISKIMINS · 2023 to 2026
$6.2M
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast CancerR01CA272771 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Boyko S Atanassov · 2023 to 2026
$1.7M
Genome-first approach to treatable genetic conditions in adultsK08HG012811 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI Nina Beth Gold · 2023 to 2026
$883k
NCI NIH HHS R01 CA272771NHGRI NIH HHS K08 HG012811NIGMS NIH HHS P30 GM145398
6 · The paper itself

Abstract

Neurodevelopmental disorders with intellectual disability (ND/ID) are a heterogeneous group of diseases driving lifelong deficits in cognition and behavior with no definitive cure. X-linked intellectual disability disorder 105 (XLID105, #300984; OMIM) is a ND/ID driven by hemizygous variants in the

Indexed as

Intellectual DisabilityX-Linked Intellectual DisabilityCell ProliferationComputational BiologyHumansNeurogenesisUbiquitin-Specific ProteasesUbiquitin-Specific ProteasesUSP27X protein, human

Identifiers

PMID38182161
PMCPMC10770416
OpenAlexW4390645748

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.